FGFR2 Assay Kit

Catalog #
79804
$535 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The FGFR2 Assay Kit is designed to measure FGFR2 activity for screening and profiling applications using Kinase-Glo® MAX as a detection reagent.

Need us to run inhibitor screens or profile your compounds against FGFR2? Check out our Kinase Screening Services.

Synonyms
FGFR2, Fibroblast Growth Factor Receptor 2, BEK, Keratinocyte Growth Factor Receptor, KGFR, JWS, CD332, FGFR-2
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Species
Human
Supplied As
The FGFR2 Assay Kit comes in a convenient 96-well format, with enough purified recombinant FGFR2, Protein Tyrosine Kinase Substrate (Poly-Glu,Tyr 4:1), ATP, and kinase assay buffer for 96 enzyme reactions.
Materials Required But Not Supplied

Kinase-Glo MAX (Promega #V6071)
Dithiothreitol (DTT, 0.5 M; optional)
Microplate reader capable of reading luminescence
Adjustable micropipettor and sterile tips
30°C incubator

Format
Catalog
Number

Reagent

Amount

Storage
40211 FGFR2, GST-Tag 5 µg -80°C

Avoid
mulitple
freeze/thaw
cylces!
79334 5x Kinase assay buffer 1.5 ml -20°C
79686 ATP (500 μM) 100 µl -20°C
40217 Protein Tyrosine Kinase Substrate
(Poly-Glu,Tyr 4:1) (10 mg/ml)
100 µl -20°C
79696 96-well plate, white 1 Room Temp.
UniProt #
P21802
Background
FGFR2 (Fibroblast Growth Factor Receptor 2) is a member of a family of tyrosine kinases involved in many pathways that play a significant role in cancer. Amplification or activation of FGFR2 has been reported in breast and gastric cancers, while FGFR2 mutations have been observed in endometrial and breast cancers. Mutations in FGFR2 are also associated with bone development disorders including Pfeiffer Syndrome and Crouzon Syndrome.
References

1. Rutland, P., et al. 1995. "Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon syndrome phenotypes." Nature Genetics 9(2): 173.
2. Xie, L., et al. 2013. "FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547." Clinical Cancer Research 9(2): 2572-2583.